PROTECTION FROM ROUTINE VACCINATION AT THE AGE OF 14 MONTHS WITH MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN THE NETHERLANDS
- 1 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 25 (1) , 79-80
- https://doi.org/10.1097/01.inf.0000195594.41449.c6
Abstract
Routine vaccination with a single dose of conjugated meningococcal C vaccine at 14 months and a catch-up campaign have reduced the incidence of meningococcal C disease in the Netherlands. In contrast to countries where routine vaccination is given in infancy, vaccine failures were not reported. This suggests that one dose of conjugated vaccine in the second year of life might offer longer lasting protection against meningococcal C disease than 3 doses in infancy.Keywords
This publication has 7 references indexed in Scilit:
- Meningococcal polysaccharide–protein conjugate vaccinesThe Lancet Infectious Diseases, 2005
- Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-makingVaccine, 2004
- The Impact of Meningococcal Serogroup C Conjugate Vaccine in ScotlandClinical Infectious Diseases, 2004
- Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decisionEurosurveillance, 2004
- Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introductionThe Lancet, 2004
- EstimatingHaemophilus influenzaeType b Vaccine Effectiveness in England and Wales by Use of the Screening MethodThe Journal of Infectious Diseases, 2003
- Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysisBMJ, 2003